Active
Mainboard

Sai Parenteral's Ltd

Sai Parenteral's Ltd IPO opened on 24 Mar 2026 and closed on 27 Mar 2026, with a price band of ₹372–₹392 per share. The IPO had a lot size of 38 shares, requiring a minimum investment of ₹14,896 per lot at the upper price band. The issue size was ₹408.79 crore, and the shares get listed on 02 Apr 2026.

Sai Parenteral's Ltd IPO Details

Listing Date

02 Apr 2026

Bid Price

₹372 - ₹392

Lot Size

38 Shares

Minimum Investment

₹14,896 / Lot

Issue Size

₹408.79 Cr

Key Dates to Track

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

24th Mar

tick

Offer End Date

27th Mar

tick

Allotment Date

30th Mar

tick

Refund Initiation

1st Apr

tick

Demat Transfer

1st Apr

tick

Listing Date

2nd Apr

About Sai Parenteral's Ltd IPO

Sai Parenteral’s Ltd., incorporated in 2001, operates in the pharmaceutical formulations segment with activities spanning research, development, and manufacturing. The company functions across two primary segments: branded generic formulations and contract development and manufacturing organisation (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins, minerals, and supplements. These products are offered in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments, reflecting a diversified formulation presence.
 

The company supplies its products to a broad customer base that includes government institutions, pharmaceutical companies, hospitals, and distribution networks within India. It commenced export operations in FY 2023 following the acquisition of two internationally accredited facilities in Hyderabad, Telangana, enabling access to regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral’s Ltd. operates five manufacturing facilities across India, including units with GMP, WHO-GMP, and international accreditations. As of December 31, 2025, the company had 298 full-time employees supporting its operations.

Sai Parenteral's Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 61.23% 51.16%
Public Group 38.77% 48.84%

Sai Parenteral's Ltd IPO Reservation

QIB Shares Offered 20,85,658 (20%)
NII (HNI) Shares Offered 15,64,243 (15%)
Retail Shares Offered 36,49,901 (35%)
Anchor Investor Shares Offered 31,28,486 (30%)
Total Shares Offered 1,04,28,288
Total Shares With Anchor Investor 1,04,28,288

Sai Parenteral's Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 38 ₹14,896
Retail (Max) 13 494 ₹1,93,648
S HNI (Min) 14 532 ₹2,08,544
S HNI (Max) 67 2,546 ₹9,98,032
B HNI (MIN) 68 2,584 ₹10,12,928

Sai Parenteral's Ltd IPO Anchor Portion Size

Bid Date March 23, 2026

Sai Parenteral's Ltd IPO registrar

Bigshare Services Pvt Ltd
Phone Number +91 22 6263 8200
Email Id ipo@bigshareonline.com
Website www.bigshareonline.com

Sai Parenteral's Ltd IPO Lead Manager

1. Arihant Capital Markets Limited

Sai Parenteral's Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹93.67 Cr ₹74.54 Cr ₹31.49 Cr
Reserves and Surplus ₹80.36 Cr ₹61.3 Cr ₹24.33 Cr
Total Borrowing ₹93.95 Cr ₹118.79 Cr ₹68.55 Cr

Sai Parenteral's Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid Subscription (Times)
Qualified Institutional Buyers (QIBs) 21,12,900 36,10,266 1.7087
Non Institutional Investors (NIIs) 16,22,876 38,31,502 2.3609
Retail Individual Investors (RIIs) 37,86,710 4,39,204 0.116
Total 75,22,486 78,80,972 1.05

Strength of Sai Parenteral's Ltd

  • Diversified generic formulations player with an established track record.
  • Strategically located and accredited Manufacturing Facilities.
  • Strong focus on CDMO business.
  • Well-established sales network in India and overseas.
  • Track record of value-accretive acquisitions.
  • Experienced Promoters and Senior Management with extensive domain knowledge.

Risks Involved

  • The company's Manufacturing Facilities are concentrated in Hyderabad, Telangana and Ongole, Andhra Pradesh. The company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
  • Out of its diversified product portfolio, approximately 44.78%, 47.64% and 92.03% during the Fiscals 2025, 2024 and 2023, respectively of the company's Net Revenue from Operations was derived from the sale of injectables. Any reduction in demand for these products may adversely affect its business, financial condition, results of operations and cash flows.
  • The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers. The company may be subject to regulatory action which may damage its reputation, leading to an adverse effect on the company's business, results of operations, financial condition and cash flows.
  • Majority of its key raw material purchases, being APIs, excipients and intermediates, are sourced from a diversified supplier base, and the company does not enter into is not any long-term contractual agreements with them. Any reduction of supplies or discontinuation of supplies from its top suppliers could have a material adverse effect on the company's business, financial condition, results of operations and cash flows. Any fluctuation in prices of its raw materials may have a material adverse effect on the company's business, results of operations, prospects and financial condition.
  • The company's success depends on its ability to successfully develop and commercialize new products in a timely manner. Any failures to do so could adversely affect the company's business, results of operations and financial condition.
  • The company's business is dependent on the sale of products to a limited number of customers for a significant portion of its revenues. The loss of one or more such customers or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.
  • The company's international business exposes us to complex management, legal, tax and economic risks, which could adversely affect its business, results of operations and financial condition.
  • There are outstanding legal proceedings involving the Company, Promoters, some of its Directors and, the company's Material Subsidiary.
  • The company plans to expand and/or upgrade its Manufacturing Facilities from the Net Proceeds of the Fresh Issue and will be required to briefly stop operations in Unit I and II till such plans are completed. The company has estimated a period of 6 months for this disruption before both these units can resume operations. The company is also dependent on third-party contractors and specialist agencies who will be executing the proposed expansion and/or upgradation plans.
  • The Indian pharmaceutical market is subject to extensive regulation and its failures to comply with the existing and future regulatory requirements in the pharmaceutical market could adversely affect the company's business, results of operations and financial condition.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Sai Parenterals IPO

  • The Indian pharmaceutical sector ranks third globally in terms of volume and was valued at approximately $62 billion in 2025.

  • Based on available estimates, the industry is projected to expand at a compound annual growth rate (CAGR) of 11.2%, reaching around $146 billion by 2033.

  • The Indian drug formulation market was estimated at nearly $47 billion in 2025.

  • This segment is projected to grow to approximately $109 billion by 2033, reflecting a CAGR of 11.2% during the period.

  • Indian contract development and manufacturing organisations (CDMOs) are expanding their role across the pharmaceutical value chain.

  • Their involvement now spans areas from drug discovery to commercialisation.

  • This expansion is observed across multiple international markets in response to evolving trends in the global pharmaceutical industry.

  • The Indian CDMO segment is expected to sustain its growth trajectory over the next 10 years.

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Sai Parenterals IPO.

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Absolute Project India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Adroit Industries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
APPL Containers Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ardee Engineering Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
EMIAC TECHNOLOGIES LIMITED IPO
Bidding Period
27th Mar 2026 - 4th Apr 2026
Price Range
₹93.0 - 98.0
IPO Size
₹32,00,00,000
SAFETY CONTROLS AND DEVICES LIMITED IPO
Bidding Period
6th Apr 2026 - 4th Apr 2026
Price Range
₹75.0 - 80.0
IPO Size
₹48,00,00,000
VIVID ELECTROMECH LIMITED IPO
Bidding Period
25th Mar 2026 - 3rd Mar 2026
Price Range
₹528.0 - 555.0
IPO Size
₹1,31,00,00,000
SAI PARENTERAL'S LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹372.0 - 392.0
IPO Size
₹4,09,00,00,000
AMIR CHAND JAGDISH KUMAR EXPORTS LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹201.0 - 212.0
IPO Size
₹4,40,00,00,000
HIGHNESS MICROELECTRONICS LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹114.0 - 120.0
IPO Size
₹22,00,00,000
POWERICA LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹375.0 - 395.0
IPO Size
₹11,00,00,00,000
TIPCO ENGINEERING INDIA LIMITED IPO
Bidding Period
23rd Mar 2026 - 3rd Mar 2026
Price Range
₹84.0 - 89.0
IPO Size
₹61,00,00,000
SPECIALITY MEDICINES LIMITED IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹117.0 - 124.0
IPO Size
₹29,00,00,000
CENTRAL MINE PLANNING AND DESIGN INSTITUTE LIMITED IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹163.0 - 172.0
IPO Size
₹18,42,00,00,000
NOVUS LOYALTY LIMITED IPO
Bidding Period
17th Mar 2026 - 3rd Mar 2026
Price Range
₹139.0 - 146.0
IPO Size
₹60,00,00,000
GSP CROP SCIENCE LIMITED IPO
Bidding Period
16th Mar 2026 - 3rd Mar 2026
Price Range
₹304.0 - 320.0
IPO Size
₹4,00,00,00,000
INNOVISION LIMITED IPO
Bidding Period
10th Mar 2026 - 3rd Mar 2026
Price Range
₹494.0 - 519.0
IPO Size
₹3,06,00,00,000
RAAJMARG INFRA INVESTMENT TRUST IPO
Bidding Period
11th Mar 2026 - 3rd Mar 2026
Price Range
₹99.0 - 100.0
IPO Size
₹60,00,00,00,000
APSIS AEROCOM LIMITED IPO
Bidding Period
11th Mar 2026 - 3rd Mar 2026
Price Range
₹104.0 - 110.0
IPO Size
₹36,00,00,000
RAJPUTANA STAINLESS LIMITED IPO
Bidding Period
9th Mar 2026 - 3rd Mar 2026
Price Range
₹116.0 - 122.0
IPO Size
₹2,55,00,00,000
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Bidding Period
6th Mar 2026 - 3rd Mar 2026
Price Range
₹91.0 - 98.0
IPO Size
₹20,00,00,000
ELFIN AGRO INDIA LIMITED IPO
Bidding Period
5th Mar 2026 - 3rd Mar 2026
Price Range
₹47.0 - 47.0
IPO Size
₹25,00,00,000
SEDEMAC MECHATRONICS LIMITED IPO
Bidding Period
4th Mar 2026 - 3rd Mar 2026
Price Range
₹1287.0 - 1352.0
IPO Size
₹10,87,00,00,000
ACETECH ECOMMERCE LIMITED IPO
Bidding Period
27th Feb 2026 - 3rd Mar 2026
Price Range
₹106.0 - 112.0
IPO Size
₹49,00,00,000
  • All
  • MainBoard
  • SME
GSP CROP SCIENCE LIMITED IPO
Issue Prize
320.00
Listing Day Close
356.10(11.25%)
INNOVISION LIMITED IPO
Issue Prize
519.00
Listing Day Close
372.80(-28.13%)
RAAJMARG INFRA INVESTMENT TRUST IPO
Issue Prize
100.00
Listing Day Close
106.83(7.00%)
APSIS AEROCOM LIMITED IPO
Issue Prize
110.00
Listing Day Close
160.65(46.36%)
RAJPUTANA STAINLESS LIMITED IPO
Issue Prize
122.00
Listing Day Close
112.90(-7.38%)
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Issue Prize
98.00
Listing Day Close
104.40(6.12%)
ELFIN AGRO INDIA LIMITED IPO
Issue Prize
47.00
Listing Day Close
47.60(2.13%)
SEDEMAC MECHATRONICS LIMITED IPO
Issue Prize
1352.00
Listing Day Close
1452.10(7.40%)
ACETECH ECOMMERCE LIMITED IPO
Issue Prize
112.00
Listing Day Close
117.60(5.36%)
STRIDERS IMPEX LIMITED IPO
Issue Prize
72.00
Listing Day Close
66.50(-6.94%)
OMNITECH ENGINEERING LIMITED IPO
Issue Prize
227.00
Listing Day Close
205.15(-9.69%)
YAAP DIGITAL LIMITED IPO
Issue Prize
145.00
Listing Day Close
133.35(-8.28%)
PNGS REVA DIAMOND JEWELLERY LIMITED IPO
Issue Prize
386.00
Listing Day Close
413.95(7.25%)
SHREE RAM TWISTEX LIMITED IPO
Issue Prize
104.00
Listing Day Close
73.45(-29.81%)
CLEAN MAX ENVIRO ENERGY SOLUTIONS LIMITED IPO
Issue Prize
1053.00
Listing Day Close
867.90(-17.57%)
MOBILISE APP LAB LIMITED IPO
Issue Prize
80.00
Listing Day Close
67.30(-16.25%)
KIAASA RETAIL LIMITED IPO
Issue Prize
127.00
Listing Day Close
116.85(-7.87%)
ACCORD TRANSFORMER AND SWITCHGEAR LIMITED IPO
Issue Prize
46.00
Listing Day Close
52.50(15.22%)
GAUDIUM IVF AND WOMEN HEALTH LIMITED IPO
Issue Prize
79.00
Listing Day Close
80.48(1.27%)
MANILAM INDUSTRIES INDIA LIMITED IPO
Issue Prize
69.00
Listing Day Close
52.45(-24.64%)

Frequently Asked Questions

What is Sai Parenteral's Ltd IPO?

Answer Field

Sai Parenteral's Ltd IPO is a Mainboard IPO of 1,04,28,288 equity shares of a face value of ₹5 aggregating up to ₹408.79 Crores. The issue is priced at ₹372 to ₹392 per share. The minimum order quantity is 38 Shares. The IPO opens on March 24, 2026, and closes on March 27, 2026. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Sai Parenteral's Ltd IPO will open?

Answer Field

The Sai Parenteral's Ltd IPO opens on March 24, 2026 and closes on March 27, 2026.

What is the lot size of Sai Parenteral's Ltd?

Answer Field

Sai Parenteral's Ltd lot size is 38 shares, and the minimum amount required is ₹14,896.

How to apply for Sai Parenteral's Ltd IPO?

Answer Field

You can apply in Sai Parenteral's Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Sai Parenteral's Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Sai Parenteral's Ltd IPO will be done on March 30, 2026, and the allotted shares will be credited to your demat account by April 01, 2026.

When is Sai Parenteral's Ltd IPO listing date?

Answer Field

The Sai Parenteral's Ltd listing date is April 02, 2026.

Who is the registrar of Sai Parenteral's Ltd IPO?

Answer Field

The registrar of Sai Parenteral's Ltd IPO is Bigshare Services Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Arihant Capital Markets Limited will be the book-running lead manager of this IPO.

What is the fresh issue of Sai Parenteral's Ltd IPO?

Answer Field

The fresh issue size is ₹285 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Sai Parenteral's Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 38 shares and ₹14,896 amount.

How can I approve the UPI mandate request for Sai Parenteral's Ltd IPO?

Answer Field

To apply for Sai Parenteral's Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Sai Parenteral's Ltd?

Answer Field

The price of each Sai Parenteral's Ltd share will be ranging in between ₹372 to ₹392 per share.

What is the cut-off time for the UPI mandate for Sai Parenteral's Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, March 27, 2026.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|